Tecan Group is a Swiss laboratory automation supplier serving life-sciences and applied-market customers with lab products and services.
3k
Public company
1Memo
What is the investment case, and what must be true for it to hold?
Tecan can sustain a return to growth because order entry climbed 3.8% in local currencies across 2025 and accelerated to 8.6% in the second half, while sales rose 6.9% in local currencies in the third quarter of 2026 with order entry up 3.1% over the same period, provided demand and margin recovery continue. Funding uncertainty and adverse foreign-exchange and tariff effects are the principal risks to that outlook.
Tecan's 2025 adjusted EBITDA margin fell to 16.1% from 17.6% in 2024, squeezed by adverse foreign-exchange effects and tariffs. The company said demand for its instruments in the Academia & Government segment was significantly hurt by budget uncertainty and volatile public funding, particularly in the US and China, during 2025.
2Risk Factors
Which risks could break the thesis, and what would warn of them?
Foreign-exchange and tariff effects threaten Tecan's margin recovery because they significantly impacted margins in 2025, when the adjusted EBITDA margin decreased to 16.1% of sales from 17.6% in 2024. Further adverse currency or tariff movements would add pressure to that margin.
Cash flow from operating activities was CHF 138.0 million in 2025, and cash conversion improved to 118% of reported EBITDA, indicating operating cash generation.